What is the recommended weekly paclitaxel (80 mg/m²) and carboplatin (AUC 2) regimen for an adult with hormone‑receptor‑positive, HER2‑negative metastatic breast cancer?

Weekly Paclitaxel/Carboplatin for HR+/HER2- Metastatic Breast Cancer

For HR-positive, HER2-negative metastatic breast cancer, single-agent chemotherapy is the standard recommendation, not combination paclitaxel/carboplatin, unless the patient has highly symptomatic or immediately life-threatening disease. 1

Guideline-Based Treatment Algorithm

First-Line Approach for HR+/HER2- MBC

The 2021 ASCO guidelines explicitly state that patients with HR-positive MBC progressing on endocrine therapy should receive single-agent chemotherapy rather than combination regimens 1. The weekly paclitaxel/carboplatin doublet you're asking about falls outside standard recommendations for this population.

When combination chemotherapy IS appropriate:

• Highly symptomatic disease requiring rapid response
• Immediately life-threatening visceral crisis
• Disease where time may allow only one chance for therapy 1

If Single-Agent Chemotherapy is Chosen

The FDA-approved paclitaxel dosing for metastatic breast cancer after failure of initial therapy is 175 mg/m² IV over 3 hours every 3 weeks 2. This is the evidence-based standard dose, not the 80 mg/m² weekly regimen combined with carboplatin.

Evidence for the Weekly Paclitaxel/Carboplatin Regimen

While the specific 80 mg/m² paclitaxel + AUC 2 carboplatin weekly regimen has been studied, the data comes from retrospective analyses and phase II trials—not the high-quality evidence that would override guideline recommendations:

• A 10-year retrospective study showed 44.7% ORR, median PFS 8.6 months, and median OS 23.7 months 3
• Critical finding: HR-positive/HER2-negative patients had reduced PFS at multivariable analysis compared to other subtypes 3
• Grade 3-4 neutropenia occurred in 16.8% of patients 3

Key Clinical Pitfalls

The major caveat: This combination regimen was actually less effective in HR+/HER2- disease compared to triple-negative or HER2-positive subtypes 3. The biology of HR+/HER2- breast cancer responds better to endocrine-based approaches or single-agent chemotherapy sequencing.

Appropriate Sequencing for HR+/HER2- MBC

1. First priority: Continue endocrine therapy with or without targeted agents (CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors) 1
2. If germline BRCA mutation present: PARP inhibitor rather than chemotherapy 1
3. When chemotherapy is needed: Single-agent taxane (paclitaxel 175 mg/m² q3weeks or 80 mg/m² weekly as monotherapy) 2

When to Consider the Weekly Doublet

The paclitaxel 80 mg/m² + carboplatin AUC 2 weekly regimen may be reasonable in:

• Visceral crisis requiring rapid cytoreduction
• Symptomatic disease burden where single-agent therapy is deemed insufficient
• After multiple prior lines when single agents have been exhausted

Premedication requirements (per FDA label): Dexamethasone 20 mg PO at 12 and 6 hours before paclitaxel, diphenhydramine 50 mg IV 30-60 minutes prior, and H2-blocker (cimetidine 300 mg or ranitidine 50 mg) IV 30-60 minutes before 2

Monitoring Requirements

• Do not administer if neutrophils <1,500/mm³ or platelets <100,000/mm³ 2
• Dose reduce by 20% for severe neutropenia (ANC <500/mm³ for ≥1 week) or severe peripheral neuropathy 2
• Monitor for cumulative neuropathy—the incidence increases with dose and duration 2

Bottom Line

Single-agent chemotherapy remains the evidence-based standard for HR+/HER2- metastatic breast cancer per current guidelines 1. The weekly paclitaxel/carboplatin combination should be reserved for specific clinical scenarios of high disease burden or visceral crisis, recognizing that this population actually shows inferior outcomes with platinum-taxane combinations compared to other breast cancer subtypes 3.